newsfilter
← Latest News
ACCESS Newswire·

Kadmon to Present 12-Month Data from Pivotal Trial of Belumosudil for cGVHD at the 62nd ASH Annual Meeting

Kadmon Holdings, Inc. (NASDAQ:KDMN) announced today that 12-month data from ROCKstar (KD025-213), the ongoing pivotal trial of belumosudil (KD025) for the treatment of chronic graft-versus-host disease (cGVHD), have been selected for oral presentation at the 62nd American Society of Hematology (ASH) Annual Meeting, taking place virtually December 5 - 8, 2020.